User:C gimpel/sandbox

= EURenOmics = EURenOmics is the name of an international research consortium on rare kidney diseases funded by the European Commission as part of the 7th framework programme.

Research activities
The main focus is the use of novel high-throughput technologies (e.g. genomics/ next generation sequencing, proteomics and metabolomics) to advance knowledge about pathogenesis and treatment of the following rare kidney diseases:
 * Steroid resistant nephrotic syndrome
 * Membranous glomerulonephritis
 * Tubulopathies
 * Complement disorders such a haemolytic uremic syndrome

The consortium's scientists have access to one of the largest rare renal disease cohorts assembled to date (collectively >12,000 patients) with detailed clinical information and comprehensive biorepositories of DNA, blood, urine, amniotic fluid and kidney tissue.
 * Congenital kidney malformations

Periodic progress reports are available on the website of the Community Research and Development Information Service (CORDIS). A large number of publications in scientific journals have been published to date. A detailed list is available on the project's website. Plain language summaries of medical advances are available in the regular newsletter.

Funding and press coverage
The total estimated total project cost is about 16 million EUR, with about 12 million EUR contributed by the EU. The project started in October 2012 and runs through September 2017. The launch of the project in Sitges, Spain in January 2013 received international press coverage in national   and local  news, medical press        as well as patient organisations  and interest groups  in the rare disease community.

Members and wider context
The consortium comprises 17 academic institutions and 10 small and medium enterprise partners from 10 European countries and the United States.

This project is receiving funding as part of the European Community’s commitment to the IRDiRC initiative (International Rare Diseases Research Consortium (IRDiRC)), which was launched in 2011 by the European Commission and the US National Institutes of Health. It collaborates closely with the RD Connect infrastructure platform and the NeurOmics project on rare neurodegenerative and neuromuscular diseases, which are also funded by the European Commission.